Study groupsa | Resistance genotypesb | n | MIC50/MIC90(mg/L) and susceptibility categorization (%)c | ||||||
---|---|---|---|---|---|---|---|---|---|
AMPc | AMCc | PIPc | CXM | CTX | MEM | ||||
Resistant group | High-rPBP3 | Group III | 1 | 8/- | 16/- | 0.06/- | >16/- | 0.25/- | 1/- |
(0/100) | (0/100) | (0/0/100) | (0/100) | (0/100/0) | |||||
Group III-like | 2 | 2/4 | 8/16 | 0.06/0.12 | >16/>16 | 0.06/0.12 | 0.03/0.03 | ||
(0/100) | (0/100) | (0/0/100) | (100/0) | (100/0/0) | |||||
Low-rPBP3 | Group II | 111 | 2/4 | 4/8 | 0.03/0.06 | 8/8 | 0.03/0.12 | 0.12/0.5 | |
(40/60) | (45/55) | (33/11/56) | (94/6) | (80/20/0) | |||||
Group I | 2 | 0.5/1 | 0.25/1 | 0.03/0.06 | 0.5/16 | 0.06/0.25 | 0.016/0.06 | ||
(100/0) | (100/0) | (50/0/50) | (50/50) | (100/0/0) | |||||
sPBP3 | 60 | 0.25/0.5 | 0.5/2 | 0.004/0.03 | 1/8 | 0.008/0.06 | 0.03/0.12 | ||
(98/2) | (98/2) | (74/13/13) | (98/2) | (100/0/0) | |||||
Susceptible group | sPBP3 | 19 | 0.12/0.5 | 0.5/2 | 0.004/0.06 | 0.5/8 | 0.004/0.03 | 0.03/0.12 | |
(100/0) | (95/5) | (79/11/11) | (100/0) | (100/0/0) |